This inventor holds 1 USPTO granted patent. Top assignee: National Institute of Health and Medical Research. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Alain Gaudric: Innovator in Angiogenesis Modulation
Introduction
Alain Gaudric is a prominent inventor based in Paris, France. He has made significant contributions to the field of medical research, particularly in the modulation of angiogenesis. His innovative work has the potential to impact therapeutic approaches for various medical conditions.
Latest Patents
Alain Gaudric holds a patent titled "Methods for modulating angiogenesis via dystrophin Dp71." This invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention highlights the role of Dp71 in angiogenesis and provides novel therapeutic approaches. It also introduces methods for screening agents that modulate angiogenesis, specifically targeting this protein. The patent outlines the use of Dp71 or its variants for stimulating angiogenesis in subjects, particularly humans. Additionally, it discusses the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject.
Career Highlights
Alain Gaudric is affiliated with the Institut National de la Santé et de la Recherche Médicale, where he conducts his research. His work has garnered attention for its innovative approach to understanding and manipulating angiogenesis.
Collaborations
Alain collaborates with notable colleagues, including Romain Bernard and Bénédicte Dupas. Their combined expertise contributes to the advancement of research in the field of angiogenesis.
Conclusion
Alain Gaudric's contributions to the modulation of angiogenesis through his innovative patent demonstrate his commitment to advancing medical research. His work holds promise for developing new therapeutic strategies in the treatment of various conditions related to angiogenesis.